Published in FEBS Lett on June 26, 2009
Methylene blue reduces aβ levels and rescues early cognitive deficit by increasing proteasome activity. Brain Pathol (2011) 1.46
Acute dosing of latrepirdine (Dimebon), a possible Alzheimer therapeutic, elevates extracellular amyloid-beta levels in vitro and in vivo. Mol Neurodegener (2009) 1.18
Cellular model of TAR DNA-binding protein 43 (TDP-43) aggregation based on its C-terminal Gln/Asn-rich region. J Biol Chem (2012) 1.08
Neuronal calcium signaling, mitochondrial dysfunction, and Alzheimer's disease. J Alzheimers Dis (2010) 1.04
Methylene blue reduced abnormal tau accumulation in P301L tau transgenic mice. PLoS One (2012) 0.98
Methylene blue protects against TDP-43 and FUS neuronal toxicity in C. elegans and D. rerio. PLoS One (2012) 0.95
The rise and fall of Dimebon. Drug News Perspect (2010) 0.92
Dimebon slows progression of proteinopathy in γ-synuclein transgenic mice. Neurotox Res (2011) 0.92
Influence of methylene blue on microglia-induced inflammation and motor neuron degeneration in the SOD1(G93A) model for ALS. PLoS One (2012) 0.89
Corticostriatal circuit dysfunction in Huntington's disease: intersection of glutamate, dopamine and calcium. Future Neurol (2010) 0.89
Latrepirdine (dimebon) enhances autophagy and reduces intracellular GFP-Aβ42 levels in yeast. J Alzheimers Dis (2012) 0.88
Latrepirdine: molecular mechanisms underlying potential therapeutic roles in Alzheimer's and other neurodegenerative diseases. Transl Psychiatry (2013) 0.87
Treatment implications of C9ORF72. Alzheimers Res Ther (2012) 0.85
An aggregation sensing reporter identifies leflunomide and teriflunomide as polyglutamine aggregate inhibitors. Hum Mol Genet (2011) 0.84
Latrepirdine, a potential novel treatment for Alzheimer's disease and Huntington's chorea. Curr Opin Investig Drugs (2010) 0.84
FUS gene mutations associated with familiar forms of amyotrophic lateral sclerosis affect cellular localization and aggregation properties of the encoded protein. Dokl Biochem Biophys (2011) 0.84
Tau-Centric Targets and Drugs in Clinical Development for the Treatment of Alzheimer's Disease. Biomed Res Int (2016) 0.81
Dimebon does not ameliorate pathological changes caused by expression of truncated (1-120) human alpha-synuclein in dopaminergic neurons of transgenic mice. Neurodegener Dis (2011) 0.77
Dimebon activates autophagosome components in human neuroblastoma SH-SY5Y cells. Dokl Biochem Biophys (2012) 0.77
Therapeutic and diagnostic challenges for frontotemporal dementia. Front Aging Neurosci (2014) 0.76
Conjugates of γ-Carbolines and Phenothiazine as new selective inhibitors of butyrylcholinesterase and blockers of NMDA receptors for Alzheimer Disease. Sci Rep (2015) 0.76
An acridine derivative, [4,5-bis{(N-carboxy methyl imidazolium)methyl}acridine] dibromide, shows anti-TDP-43 aggregation effect in ALS disease models. Sci Rep (2016) 0.75
The Effects of Latrepirdine on Amyloid-β Aggregation and Toxicity. J Alzheimers Dis (2016) 0.75
Gamma-carboline inhibits neurodegenerative processes in a transgenic model of amyotrophic lateral sclerosis. Dokl Biochem Biophys (2015) 0.75
TDP-43 is a component of ubiquitin-positive tau-negative inclusions in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Biochem Biophys Res Commun (2006) 10.69
Transmission and spreading of tauopathy in transgenic mouse brain. Nat Cell Biol (2009) 7.50
Continuous cell supply from a Sox9-expressing progenitor zone in adult liver, exocrine pancreas and intestine. Nat Genet (2010) 6.81
alpha-Synuclein is phosphorylated in synucleinopathy lesions. Nat Cell Biol (2002) 6.64
Nomenclature and nosology for neuropathologic subtypes of frontotemporal lobar degeneration: an update. Acta Neuropathol (2009) 4.73
Nomenclature for neuropathologic subtypes of frontotemporal lobar degeneration: consensus recommendations. Acta Neuropathol (2008) 4.73
GSK3 inhibitors: development and therapeutic potential. Nat Rev Drug Discov (2004) 3.93
Identification of Sox9-dependent acinar-to-ductal reprogramming as the principal mechanism for initiation of pancreatic ductal adenocarcinoma. Cancer Cell (2012) 3.36
Phosphorylated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Ann Neurol (2008) 3.13
Prion-like spreading of pathological α-synuclein in brain. Brain (2013) 2.92
Abundant tau filaments and nonapoptotic neurodegeneration in transgenic mice expressing human P301S tau protein. J Neurosci (2002) 2.80
Drug screening for ALS using patient-specific induced pluripotent stem cells. Sci Transl Med (2012) 2.80
Tau pathology and neurodegeneration. Lancet Neurol (2013) 2.66
Sox9 is required for determination of the chondrogenic cell lineage in the cranial neural crest. Proc Natl Acad Sci U S A (2003) 2.64
Longer forms of amyloid beta protein: implications for the mechanism of intramembrane cleavage by gamma-secretase. J Neurosci (2005) 2.48
Misfolded proteinase K-resistant hyperphosphorylated alpha-synuclein in aged transgenic mice with locomotor deterioration and in human alpha-synucleinopathies. J Clin Invest (2002) 2.47
Brain homogenates from human tauopathies induce tau inclusions in mouse brain. Proc Natl Acad Sci U S A (2013) 2.27
Uncoupling Sonic hedgehog control of pattern and expansion of the developing limb bud. Dev Cell (2008) 2.25
TDP-43 is deposited in the Guam parkinsonism-dementia complex brains. Brain (2007) 2.25
Truncation and pathogenic mutations facilitate the formation of intracellular aggregates of TDP-43. Hum Mol Genet (2009) 2.23
Inhibition of heparin-induced tau filament formation by phenothiazines, polyphenols, and porphyrins. J Biol Chem (2004) 2.11
Biophysical properties of the synucleins and their propensities to fibrillate: inhibition of alpha-synuclein assembly by beta- and gamma-synucleins. J Biol Chem (2002) 2.07
Repeat motifs of tau bind to the insides of microtubules in the absence of taxol. EMBO J (2003) 2.07
Phosphorylated TDP-43 in Alzheimer's disease and dementia with Lewy bodies. Acta Neuropathol (2009) 2.01
Seeded aggregation and toxicity of {alpha}-synuclein and tau: cellular models of neurodegenerative diseases. J Biol Chem (2010) 1.92
Hyperphosphorylation and insolubility of alpha-synuclein in transgenic mouse oligodendrocytes. EMBO Rep (2002) 1.91
p38gamma regulates the localisation of SAP97 in the cytoskeleton by modulating its interaction with GKAP. EMBO J (2005) 1.90
Relationship of phosphorylated alpha-synuclein and tau accumulation to Abeta deposition in the cerebral cortex of dementia with Lewy bodies. Exp Neurol (2007) 1.89
Proteasomal degradation of tau protein. J Neurochem (2002) 1.88
αβγ-Synuclein triple knockout mice reveal age-dependent neuronal dysfunction. Proc Natl Acad Sci U S A (2010) 1.83
Biochemical characterization of the core structure of alpha-synuclein filaments. J Biol Chem (2002) 1.77
Submandibular gland biopsy for the diagnosis of Parkinson disease. J Neuropathol Exp Neurol (2013) 1.77
Abnormal phosphorylation of Ser409/410 of TDP-43 in FTLD-U and ALS. FEBS Lett (2008) 1.76
Phosphorylated alpha-synuclein is ubiquitinated in alpha-synucleinopathy lesions. J Biol Chem (2002) 1.71
Small molecule inhibitors of alpha-synuclein filament assembly. Biochemistry (2006) 1.69
Tau filaments from human brain and from in vitro assembly of recombinant protein show cross-beta structure. Proc Natl Acad Sci U S A (2003) 1.67
Mutation E46K increases phospholipid binding and assembly into filaments of human alpha-synuclein. FEBS Lett (2004) 1.60
Accumulation of phosphorylated alpha-synuclein in aging human brain. J Neuropathol Exp Neurol (2003) 1.59
Pathological changes in dopaminergic nerve cells of the substantia nigra and olfactory bulb in mice transgenic for truncated human alpha-synuclein(1-120): implications for Lewy body disorders. J Neurosci (2006) 1.57
Colocalization of transactivation-responsive DNA-binding protein 43 and huntingtin in inclusions of Huntington disease. J Neuropathol Exp Neurol (2008) 1.56
Positive regulation of adult bone formation by osteoblast-specific transcription factor osterix. J Bone Miner Res (2009) 1.56
Functional alterations to the nigrostriatal system in mice lacking all three members of the synuclein family. J Neurosci (2011) 1.56
Stimulation of autophagy reduces neurodegeneration in a mouse model of human tauopathy. Brain (2012) 1.55
Neurons expressing the highest levels of gamma-synuclein are unaffected by targeted inactivation of the gene. Mol Cell Biol (2003) 1.53
Osteoblast-targeted expression of Sfrp4 in mice results in low bone mass. J Bone Miner Res (2008) 1.52
Developmental loss and resistance to MPTP toxicity of dopaminergic neurones in substantia nigra pars compacta of gamma-synuclein, alpha-synuclein and double alpha/gamma-synuclein null mutant mice. J Neurochem (2004) 1.50
α-Synuclein and dopamine at the crossroads of Parkinson's disease. Trends Neurosci (2010) 1.49
Prion-like properties of pathological TDP-43 aggregates from diseased brains. Cell Rep (2013) 1.49
Part II: alpha-synuclein and its molecular pathophysiological role in neurodegenerative disease. Neuropharmacology (2003) 1.48
Myelination transition zone astrocytes are constitutively phagocytic and have synuclein dependent reactivity in glaucoma. Proc Natl Acad Sci U S A (2011) 1.47
Sox9-expressing precursors are the cellular origin of the cruciate ligament of the knee joint and the limb tendons. Genesis (2010) 1.46
LRRK2 expression in normal and pathologic human brain and in human cell lines. J Neuropathol Exp Neurol (2006) 1.46
Occurrence of T cells in the brain of Alzheimer's disease and other neurological diseases. J Neuroimmunol (2002) 1.45
Secreted frizzled-related protein 4 is a negative regulator of peak BMD in SAMP6 mice. J Bone Miner Res (2006) 1.43
Abeta and tau form soluble complexes that may promote self aggregation of both into the insoluble forms observed in Alzheimer's disease. Proc Natl Acad Sci U S A (2006) 1.41
Absence of alpha-synuclein affects dopamine metabolism and synaptic markers in the striatum of aging mice. Neurobiol Aging (2008) 1.41
SNARE protein redistribution and synaptic failure in a transgenic mouse model of Parkinson's disease. Brain (2010) 1.38
Increased striatal dopamine release and hyperdopaminergic-like behaviour in mice lacking both alpha-synuclein and gamma-synuclein. Eur J Neurosci (2008) 1.38
Gamma-synucleinopathy: neurodegeneration associated with overexpression of the mouse protein. Hum Mol Genet (2009) 1.37
Fecal transmission of AA amyloidosis in the cheetah contributes to high incidence of disease. Proc Natl Acad Sci U S A (2008) 1.36
Reticulons RTN3 and RTN4-B/C interact with BACE1 and inhibit its ability to produce amyloid beta-protein. Eur J Neurosci (2006) 1.36
Parkinson's disease alpha-synuclein mutations exhibit defective axonal transport in cultured neurons. J Cell Sci (2004) 1.36
Interaction of tau protein with the dynactin complex. EMBO J (2007) 1.33
A novel in vivo model of tau propagation with rapid and progressive neurofibrillary tangle pathology: the pattern of spread is determined by connectivity, not proximity. Acta Neuropathol (2014) 1.32
Analysis of tau phosphorylation and truncation in a mouse model of human tauopathy. Am J Pathol (2007) 1.32
Dipeptide repeat proteins are present in the p62 positive inclusions in patients with frontotemporal lobar degeneration and motor neurone disease associated with expansions in C9ORF72. Acta Neuropathol Commun (2013) 1.32
PART is part of Alzheimer disease. Acta Neuropathol (2015) 1.31
Sox9 sustains chondrocyte survival and hypertrophy in part through Pik3ca-Akt pathways. Development (2011) 1.30
Conversion of wild-type alpha-synuclein into mutant-type fibrils and its propagation in the presence of A30P mutant. J Biol Chem (2009) 1.29